You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALK Tyrosine Kinase Inhibitor

Showing 1 - 25 of 9,803
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

Non Small Cell Lung Cancer, NSCLC, NSCLC Trial in Australia, Korea, Republic of, United States (TPX-0131)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • +5 more
  • Orange, California
  • +13 more
Nov 7, 2022

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

NSCLC Trial in Germany (Brigatinib, Tyrosine kinase inhibitor)

Recruiting
  • NSCLC
  • Berlin, Germany
  • +25 more
Nov 10, 2022

Carcinoma, Non-Small-Cell Lung Trial in Worldwide (Lorlatinib)

Recruiting
  • Carcinoma
  • Non-Small-Cell Lung
  • Orange, California
  • +31 more
Dec 6, 2022

Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase

Recruiting
  • Liver Transplant
  • PVHA or TACE
  • Shanghai, Shanghai, China
    The value of tumor feeding vessels deprivation combined with tyr
Nov 26, 2022

NSCLC ALK-positive, NSCLC c-Met Dependent, NSCLC ROS Marker Positive Trial in Worldwide (PF-02341066, Rifampin, Itraconazole)

Completed
Has Results
  • Non-Small Cell Lung Cancer ALK-positive
  • +4 more
  • Orange, California
  • +28 more
Feb 15, 2022

Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

Recruiting
  • Liver Neoplasms
  • Tislelizumab plus tyrosine kinase inhibitor
  • Beijing, Beijing, China
    302 Hospital
Sep 22, 2023

CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

Recruiting
  • CML
  • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
  • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
    FUNDALEU
Jun 29, 2023

Acute Lymphoblastic Leukemia Trial in Ann Arbor (Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Nov 28, 2022

Breast Cancer Trial in Guangzhou (Take probiotics)

Recruiting
  • Breast Cancer
  • Take probiotics
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Mar 6, 2023

Non-small-cell Lung Carcinoma Trial in Beijing (SY-3505)

Recruiting
  • Non-small-cell Lung Carcinoma
  • Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
May 11, 2023

Gastrointestinal Stromal Tumors (GISTs) Trial in Seoul (Imatinib Mesylate)

Completed
  • Gastrointestinal Stromal Tumors (GISTs)
  • Imatinib Mesylate
  • Seoul, Korea, Republic of
    Asan Medical Center
Dec 30, 2022

Lung Tumors Trial (Camrelizumab, Apatinib, Pemetrixed)

Not yet recruiting
  • Lung Neoplasms
  • (no location specified)
Jun 8, 2020

Multiple Sclerosis Trial run by the National Institute of Neurological Disorders and Stroke (NINDS) (tolebrutinib 60mg,

Active, not recruiting
  • Multiple Sclerosis
  • tolebrutinib 60mg
  • tolebrutinib 120mg
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • East Melbourne, Victoria, Australia
  • +7 more
Jan 20, 2023

Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor Trial in Rotterdam

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
    • Rotterdam, Netherlands
      Erasmus MC
    Feb 2, 2022

    Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

    Withdrawn
    • Non-Small Cell Lung Cancer
    • InVisionFirst-Lung ctDNA assay
    • Los Angeles, California
    • +2 more
    Sep 16, 2022

    ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Pure

    Completed
    • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Sep 23, 2021

    Advanced Malignant Tumor, BRAF Gene Mutation, Metastatic Malignant Tumor Trial in Houston (Crizotinib, Laboratory Biomarker

    Completed
    • Advanced Malignant Neoplasm
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 19, 2021

    Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia

    Not yet recruiting
    • Tyrosine Kinase Inhibitor
    • +2 more
      • Taipei, Taiwan
        National Taiwan University Hospital
      Feb 17, 2022

      Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive Trial in New York (Blinatumomab, dasatinib, dexamethasone)

      Recruiting
      • Acute Lymphoblastic Leukemia
      • Philadelphia Chromosome-Positive
      • Blinatumomab
      • +3 more
      • New York, New York
      • +1 more
      Nov 10, 2022

      High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Surufatinib, Sintilimab, Radiotherapy)

      Recruiting
      • High-Risk Localized Soft Tissue Sarcoma
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Apr 20, 2023

      HRQOL in Locally Advanced Thyroid Carcinoma

      Recruiting
      • Thyroid Cancer
      • +2 more
      • Tyrosine kinase inhibitor drugs.
      • Fuzhou, Fujian, China
        Road Fuma No.420
      Apr 11, 2023

      Liposarcoma, Metastatic Liposarcoma Trial in Boston, Saint Louis, New York (MGCD516)

      Active, not recruiting
      • Liposarcoma
      • Metastatic Liposarcoma
      • Boston, Massachusetts
      • +2 more
      Nov 23, 2022